What is Allogene Therapeutics's gross unrealized gains?

Allogene Therapeutics (ALLO) reported gross unrealized gains of $66K in Q1 2026.

How has Allogene Therapeutics's gross unrealized gains changed year-over-year?

Allogene Therapeutics's gross unrealized gains decreased by 53.2% year-over-year, from $141K to $66K.

What is the long-term trend for Allogene Therapeutics's gross unrealized gains?

Over 5 years (2020 to 2025), Allogene Therapeutics's gross unrealized gains has grown at a -18.2% compound annual growth rate (CAGR), from $764K to $279K.

Allogene Therapeutics ALLO Gross Unrealized Gains

Gross Unrealized Gains at other companies

Gilead SciencesGILD

——

PrecigenPGEN

——

Artiva Biotherapeutics, Inc.ARTV

——

Arcus BiosciencesRCUS

——

Vir Biotechnology, Inc.VIR

——

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's gross unrealized gains?: Allogene Therapeutics (ALLO) reported gross unrealized gains of $66K in Q1 2026.
How has Allogene Therapeutics's gross unrealized gains changed year-over-year?: Allogene Therapeutics's gross unrealized gains decreased by 53.2% year-over-year, from $141K to $66K.
What is the long-term trend for Allogene Therapeutics's gross unrealized gains?: Over 5 years (2020 to 2025), Allogene Therapeutics's gross unrealized gains has grown at a -18.2% compound annual growth rate (CAGR), from $764K to $279K.